2NaKamolo T , Inagawa H , TaKagiK , el al . A new method of anlilumor therapy with a high dose TNF perfusion for unresectable liver turners[J]. Anticancer Res, 2000,20(6A):4087-4096.
3Nakamura S , Kato A , Masegi T , et al .A novel recombinantumor necrosis factor-alpha , mutant with increased anti-tumor activity and lower toxicity [J]. Int Cancer, 1991,48(5):744-748.
2[1]Lee KY, Chang W, Qiu D, et al. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem,1999,274(19)∶13451-13455.
3[2]Stein U, Walther W, Shoemaker RH. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst,1996,88 (19)∶1383-1392.
4[3]Lasek W, Giermasz A, Kuc K, et al. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results. Int J Cancer,1996,66(3)∶374-379.
5[5]Chcialowski A, Targowski T, Bajera I, et al. Tumor necrosis factor-alpha--phase Ⅰ and phase Ⅱ clinical trials. Pol Merkuriusz Lek,1997,2(12)∶396-399.
6[6]Tomita A, Fuchino Y, Otsuka K, et al. Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients. Anticancer Res,1998,18(5D)∶3937-3939.
7[7]Fukushima T, Yamamoto M, Ikeda K, et al. Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res,1998,18(5D)∶3965-3970.
8Eggermont AMM, Schreffordt KH, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial[J]. Clin Oncol, 1996, 14:2653-2665.
9Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma[J]. Clin Oncol, 1992, 10: 52-60.
10Eggermont AMM. TNF registered in Europe: Does TNF get a second chance? [ J]. J Immunotherapy, 2000, 23: 505-506.
